Medros Overview

  • Founded
  • 2006
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Medros General Information


Operator of a drug discovery company and contract research organization. The company utilizes Drosophila for discovery of cancer metastasis as well as diabetes and metabolism-related drugs, thus providing contract research services to pharmaceutical and biotechnology companies.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Other Healthcare Services
Primary Office
  • 4041 Forest Park Avenue
  • Saint Louis, MO 63108
  • United States
+1 (314) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medros Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Jun-2014 00000 Completed Out of Business
4. Grant 06-Sep-2012 00000 00000 Completed Generating Revenue
3. Grant 31-Aug-2011 00000 00000 Completed Startup
2. Grant 07-Mar-2010 $465K $500K Completed Startup
1. Seed Round 01-Jan-2006 $500K $500K 000 Completed Startup
To view Medros’s complete valuation and funding history, request access »

Medros Executive Team (5)

Name Title Board Seat Contact Info
Robert Karr MD President & Chief Executive Officer
Ross Cagan Co-Founder & Board Member
Thomas Baranski Co-Founder & Board Member
Philip Needleman Scientific Advisor
Andrew Hoyne JD General Counsel, Secretary & Board Member
To view Medros’s complete executive team members history, request access »

Medros Board Members (5)

Name Representing Role Since
Andrew Hoyne JD Self General Counsel, Secretary & Board Member 000 0000
Ross Cagan Medros Co-Founder & Board Member 000 0000
Thomas Baranski Medros Co-Founder & Board Member 000 0000
You’re viewing 3 of 5 board members. Get the full list »